Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 1997-10-01 (28 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: MONTPELLIER (34070), Herault
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE PEDRO DE LUNA : revenue, balance sheet and financial ratios
PHARMACIE PEDRO DE LUNA is a French company
founded 28 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MONTPELLIER (34070),
this company of category PME
shows in 2025 a net income positive of 113 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE PEDRO DE LUNA (SIREN 414195081)
Indicator
2025
2024
2023
2022
2021
2020
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
113 181 €
127 896 €
136 544 €
140 825 €
58 818 €
49 850 €
81 559 €
64 912 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE PEDRO DE LUNA generates positive net income of 113 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 65 k€ -> 113 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
113 181 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 36%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 62%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
35.658%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
62.277%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE PEDRO DE LUNA
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2020
2021
2022
2023
2024
2025
Debt ratio
251.642
186.19
92.237
79.68
63.067
52.042
42.981
35.658
Financial autonomy
24.82
29.268
44.096
49.924
51.196
57.769
58.532
62.277
Repayment capacity
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
35.662025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good
In 2025, the debt ratio of PHARMACIE PEDRO DE LUNA (35.66) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
62.28%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good
In 2025, the financial autonomy of PHARMACIE PEDRO DE LUNA (62.3%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 156.74. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
156.739
Liquidity indicators evolution PHARMACIE PEDRO DE LUNA
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2020
2021
2022
2023
2024
2025
Liquidity ratio
255.973
199.152
119.285
90.81
165.028
170.771
153.436
156.739
Interest coverage
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
156.742025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Average
In 2025, the liquidity ratio of PHARMACIE PEDRO DE LUNA (156.74) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Positioning of PHARMACIE PEDRO DE LUNA in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE PEDRO DE LUNA is estimated at
1 797 893 €
(range 1 220 059€ - 2 821 142€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1220k€1797k€2821k€
1 797 893 €Range: 1 220 059€ - 2 821 142€
NAF 5 année 2025
Valuation method used
Net Income Multiple
113 181 €
×
15.9x
=1 797 894 €
Range: 1 220 059€ - 2 821 143€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE PEDRO DE LUNA with other companies in the same sector:
Frequently asked questions about PHARMACIE PEDRO DE LUNA
What is the revenue of PHARMACIE PEDRO DE LUNA ?
The revenue of PHARMACIE PEDRO DE LUNA is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIE PEDRO DE LUNA profitable?
Yes, PHARMACIE PEDRO DE LUNA generated a net profit of 113 k€ in 2025.
Where is the headquarters of PHARMACIE PEDRO DE LUNA ?
The headquarters of PHARMACIE PEDRO DE LUNA is located in MONTPELLIER (34070), in the department Herault.
Where to find the tax return of PHARMACIE PEDRO DE LUNA ?
The tax return of PHARMACIE PEDRO DE LUNA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE PEDRO DE LUNA operate?
PHARMACIE PEDRO DE LUNA operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart